A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Primary immune thrombocytopenia (ITP) is a rare disease that results in low levels of
platelets - the cells that help blood clot.
The main aim of the study is to check for side effects from taking TAK-079 at three different
dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people
with ITP.
In addition to receiving stable background therapy for ITP, participants will receive an
injection of either TAK-079 or a placebo once a week for 2 months. A placebo looks like
TAK-079 but will not have any medicine in it. After treatment, all participants will be
followed-up for another 2 months.
Then, participants who received TAK-079 will continue to be followed-up for an extra 4
months. Participants who received the placebo and would like to receive TAK-079 may be able
to do this in an extension period in the study.